Natural Capsules Limited
Natural Capsules Limited engages in the manufacture and sale of hard gelatin and cellulose capsule shells in India and internationally. The company offers bovine spongiform encephalopathy and transmissible spongiform encephalopathy-free gelatin, shiny gelatin, sodium lauryl sulfate-free gelatin, halal-certified gelatin, fast-release gelatin, printed gelatin/cellulose, vegetarian, and enteric caps… Read more
Natural Capsules Limited (NATCAPSUQ) - Net Assets
Latest net assets as of September 2025: ₹2.45 Billion INR
Based on the latest financial reports, Natural Capsules Limited (NATCAPSUQ) has net assets worth ₹2.45 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹4.20 Billion) and total liabilities (₹1.75 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹2.45 Billion |
| % of Total Assets | 58.43% |
| Annual Growth Rate | 45.78% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 27.37 |
Natural Capsules Limited - Net Assets Trend (2022–2025)
This chart illustrates how Natural Capsules Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Natural Capsules Limited (2022–2025)
The table below shows the annual net assets of Natural Capsules Limited from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹2.57 Billion | +12.39% |
| 2024-03-31 | ₹2.29 Billion | +54.34% |
| 2023-03-31 | ₹1.48 Billion | +78.65% |
| 2022-03-31 | ₹829.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Natural Capsules Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 42.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹794.95 Million | 34.13% |
| Common Stock | ₹103.41 Million | 4.44% |
| Other Components | ₹1.43 Billion | 61.43% |
| Total Equity | ₹2.33 Billion | 100.00% |
Natural Capsules Limited Competitors by Market Cap
The table below lists competitors of Natural Capsules Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jeju Beer Co. Ltd.
KQ:276730
|
$6.23 Million |
|
2BO
F:2BO
|
$6.23 Million |
|
Kanoria Chemicals & Industries Limited
NSE:KANORICHEM
|
$6.24 Million |
|
Electric Royalties Ltd
OTCQB:ELECF
|
$6.24 Million |
|
AIM ImmunoTech Inc
NYSE MKT:AIM
|
$6.23 Million |
|
Zhong Yang Financial Group Limited Ordinary Shares
NASDAQ:TOP
|
$6.23 Million |
|
CATERPILLAR - Dusseldorf Stock Exchang
DU:CAT1
|
$6.23 Million |
|
Malam Team
TA:MLTM
|
$6.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Natural Capsules Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,038,001,000 to 2,329,361,000, a change of 291,360,000 (14.3%).
- Net income of 6,174,000 contributed positively to equity growth.
- New share issuances of 278,365,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹6.17 Million | +0.27% |
| Share Issuances | ₹278.37 Million | +11.95% |
| Other Changes | ₹6.82 Million | +0.29% |
| Total Change | ₹- | 14.30% |
Book Value vs Market Value Analysis
This analysis compares Natural Capsules Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.70x to 0.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | ₹88.76 | ₹151.28 | x |
| 2023-03-31 | ₹132.85 | ₹151.28 | x |
| 2024-03-31 | ₹217.99 | ₹151.28 | x |
| 2025-03-31 | ₹236.82 | ₹151.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Natural Capsules Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.38%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.80x
- Recent ROE (0.27%) is below the historical average (8.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 16.77% | 10.71% | 0.79x | 1.98x | ₹56.16 Million |
| 2023 | 14.97% | 11.20% | 0.57x | 2.34x | ₹61.24 Million |
| 2024 | 2.72% | 3.67% | 0.40x | 1.85x | ₹-148.27 Million |
| 2025 | 0.27% | 0.38% | 0.39x | 1.80x | ₹-226.76 Million |
Industry Comparison
This section compares Natural Capsules Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Natural Capsules Limited (NATCAPSUQ) | ₹2.45 Billion | 16.77% | 0.71x | $6.23 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |